Ukrainian Pharmaceutical Industry Revitalising and Developing Despite the Challenges of War According to the Ukrainian Pharmaceutical Industry-2023 Study

Darnytsia Pharmaceutical Company has presented Ukrainian Pharmaceutical Industry-2023 Study prepared in partnership with Top Lead and Proxima Research.

Last year, the industry saw active revitalisation. Despite all the challenges including a sharp drop in the purchasing power of the population and logistical issues, pharmaceutical industry remains one of the leading Ukrainian industries. 

In 2023, the sales volume increased by 19.6% compared with 2022. 

As for pharmacies, medicinal products of Ukrainian origin traditionally prevail over imported ones and take up 63% of the product range; however, the total sales value of the imported medicinal products is 63% of the gross proceeds. 

Export of pharmaceuticals increased by 17.2% in 2023 compared with 2022. The leading importers of Ukrainian pharmaceuticals are Uzbekistan, Kazakhstan, Lithuania, Georgia and Moldova. 

At the same time, import of pharmaceuticals to Ukraine increased by 12.6% compared with 2022. The leading exporters are Germany, India and France. 

Despite lingering safety concerns, the majority of the Ukrainian pharmaceutical companies in 2023  either increased research and development spending or kept it on the same level as in 2022. 

For more information about the study and its results, click this link. 

‘Pharmaceutical industry was always in the needs of active introduction of innovations, recruitment of highly qualified professionals and maintenance of sustainable business practices. Therefore, the leading Ukrainian pharmaceutical companies such as Darnytsia did not back down in the face of a full-blown war. These factors are sure to continue contributing to further development of the industry,’ said Vasyl Hubarets, Corporate Communications Director, Darnytsia Pharmaceutical Company.